Pranlukast treatment and the use of respiratory support in infants with respiratory syncytial virus infection.

Abstract

BACKGROUND:

In infants, respiratory syncytial virus (RSV) infection occasionally causes severe symptoms requiring respiratory support; however, supportive care is the primary treatment. This study compared the use of respiratory support among infants with RSV infection treated with or without pranlukast.

METHODS:

This retrospective cohort study included infants aged <10 months with RSV infection who were admitted to three secondary level hospitals in Japan between 2012 and 2019. The infants were divided into two groups depending on whether they were treated with pranlukast. The primary outcome was the receiving respiratory support (high-flow nasal cannula, nasal continuous positive airway pressure, or ventilator). The secondary outcomes were the length of hospital stay, and the Global Respiratory Severity Score (GRSS) on starting respiratory support or at the time of the worst signs during hospitalization. We performed a propensity score-matched analysis.

RESULTS:

A total of 492 infants, including 147 propensity score-matched pairs, were included in the analysis. The use of respiratory support was significantly lower in infants treated with pranlukast (3.4% [5/147]) than those treated without pranlukast (11.6% [17/147]; P = 0.01). In the propensity score-matched analysis, pranlukast use was associated with a significantly lower chance of needing respiratory support (odds ratio: 0.27, 95% confidence interval: 0.08-0.79; P = 0.01); however, the length of hospital stay (median: 4 days) and the GRSS (median: 2.804 and 2.869 for infants treated with and without pranlukast, respectively) did not differ significantly between propensity score-matched pairs.

CONCLUSIONS:

Pranlukast use was associated with a reduced likelihood of requiring respiratory support in infants aged <10 months with RSV infection.

• Authors: Jun Kubota, Sho Takahashi, Takayuki Suzuki, Akira Ito, Naoe Akiyama, Noriko Takahata
• Journal: PloS one (PLoS One) Vol. 17 Issue 5 Pg. e0269043 ( 2022) ISSN: 1932-6203 [Electronic] United States
• PMID: 35622830 (Publication Type: Journal Article)

Chemical References

• Chromones
• pranlukast

Topics

• Chromones
• Hospitalization
• Humans
• Infant
• Length of Stay
• Respiratory Syncytial Virus Infections (therapy)
• Retrospective Studies